20 articles
Dasatinib and quercetin, a leading senolytic combo, unexpectedly reduced myelination in healthy mouse brains, mimicking multiple sclerosis damage.
New mouse research finds the trendy D+Q senolytic combo severely damages myelin, raising red flags for longevity self-experimenters.
Scientists found drugs that kill senescent 'zombie cells' by blocking their key survival protein, shrinking tumors in mice.
Fisetin is emerging as a top senolytic candidate, clearing senescent cells linked to aging — and strawberries are its richest dietary source.
Rubedo's RLS-1496 reduced actinic keratosis lesions by 46% in four weeks with minimal side effects, targeting aging cells behind the damage.
Mountain View biotech's RLS-1496 becomes first GPX4-targeting senolytic to enter human trials, using AI platform to eliminate aging cells.
A quercetin, NR, urolithin A, and alpha-lipoic acid combination boosted remaining lifespan in aged mice by 33%, even on a Western diet.
Rubedo's RLS-1496 demonstrates early clinical signals in removing senescent cells through GPX4 modulation in human skin tissue.
A topical senolytic drug cleared aging 'zombie' cells from old skin, helping aged mice heal wounds 43% more completely by day 24.
Researchers identified polyunsaturated fatty acids that may help eliminate senescent cells linked to aging and disease.
Rubedo's RLS-1496 cream slashed actinic keratosis lesions nearly in half at 4 weeks with no serious side effects in early trial data.
New research reveals antioxidants can selectively eliminate senescent muscle cells by correcting faulty mTOR nutrient-sensing pathways linked to aging.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Biotech company Rubedo announces preliminary positive results for RLS-1496, a drug targeting aging cells for cellular rejuvenation.
Seragon's oral combo therapy SRN-901 outperforms rapamycin in mice, boosting lifespan and slashing frailty through multi-pathway aging intervention.
Cyclarity's UDP-003 shows first human evidence of excreting oxidized cholesterol, pointing toward reversing arterial damage rather than just slowing it.
Cyclarity Therapeutics reveals clinical data showing UDP-003 can safely excrete 7-ketocholesterol, a root driver of arterial plaque, from the human body.
Cyclarity's UDP-003 passed its first human trial with zero serious side effects, successfully flushing toxic 7-ketocholesterol through urine.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
New research reveals primary and secondary senescent cells behave differently, opening targeted paths to slow aging at the cellular level.
